Breast cancer is the world’s most common cancer among women and is a leading cause of death in women. Metabolic components are important risk factors for non-alcoholic fatty liver disease (NAFLD) growth, as with breast cancer. This interview uncovers the prevalence of NAFLD in breast cancer patients and the influence of NAFLD on the prognosis of breast cancer in this retrospective cohort analysis.
Advances in imaging technologies and breast cancer care modalities have contributed to mortality decreases in breast cancer patients. FibroScan®, for example, is an FDA cleared technology for the diagnosis and monitoring of adult patients as part of an overall evaluation of liver health. Unlike blood tests that measure circulating markers of inflammation, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), this tool directly and non-invasively measures physical properties of stiffness and liver fat.
When it comes to a breast cancer patient’s elevated risk for liver disease, primary care physicians, hematologists and oncologists should consider integrating FibroScan® for both diagnosis and monitoring of liver stiffness and liver fat.